Two-Pronged attack: experimental therapy targets tough lymphomas

NCT ID NCT05421663

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This study is testing a new type of personalized immune cell therapy called prizlo-cel for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments, or for those with newly diagnosed high-risk disease. The therapy involves collecting a patient's own immune cells, genetically modifying them to recognize two cancer markers (CD19 and CD20), and reinfusing them to attack the lymphoma. The research aims to determine the safety, optimal dose, and effectiveness of this dual-targeting approach in controlling the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Calvary Mater Newcastle Hospital
COMPLETED

Waratah, 2298, Australia
City of Hope
RECRUITING

Duarte, California, 91010, United States
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Erasmus MC
RECRUITING

Rotterdam, 3015 GD, Netherlands
Fiona Stanley Hospital
RECRUITING

Murdoch, 6150, Australia
Greco Hainesworth Tennessee Oncology Centers for Research
RECRUITING

Nashville, Tennessee, 37203, United States
Hosp Clinic de Barcelona
RECRUITING

Barcelona, 08036, Spain
Hosp Univ Fund Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hosp Univ Vall D Hebron
RECRUITING

Barcelona, 08035, Spain
ICO L'Hospitalet - Hospital Duran i Reynals
RECRUITING

Barcelona, 08908, Spain
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28001, United States
Odense University Hospital
RECRUITING

Odense, 5000, Denmark
Princess Margaret Cancer Centre University Health Network
RECRUITING

Toronto, Ontario, M5G2M9, Canada
Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark
Rutgers Cancer Institute of New Jersey
RECRUITING

Piscataway, New Jersey, 08854, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
St Vincents Hospital Melbourne
RECRUITING

Fitzroy, 3065, Australia
St. David's South Austin Medical Center
RECRUITING

Austin, Texas, 78704, United States
Swedish Cancer Institute
RECRUITING

Seattle, Washington, 98104, United States
Texas Transplant Institute
RECRUITING

San Antonio, Texas, 78229, United States
The Alfred Hospital
RECRUITING

Melbourne, 3004, Australia
The Christie NHS Foundation Trust Christie Hospital
RECRUITING

Manchester, M20 4BX, United Kingdom
UMC Utrecht
RECRUITING

Utrecht, 3584 CX, Netherlands
University College London Hospitals
RECRUITING

London, NW1 2BU, United Kingdom
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of Iowa Hospital and Clinics
RECRUITING

Iowa City, Iowa, 52242, United States
University of Kentucky Medical Center
RECRUITING

Lexington, Kentucky, 40536, United States
University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.

LYMPHOMA, B-CELL LYMPHOMA, LARGE B-CELL, DIFFUSE LYMPHOMA, NON-HODGKIN